Eric Doerr

Featured in: Favicon

bioprocessonline.com Favicon

outsourcedpharma.com

Articles

07.18.24 -- Emerging Biotechs Judge CDMOs More Harshly

Jul 18, 2024 | outsourcedpharma.com | Louis Garguilo |Eric Doerr |JD Williams |Wen-Rong Jiang

Mabion Capacity Update May 2024: Large Molecule DevelopmentReview our installations in upstream development, downstream development, and fill & finish. Our state-of-the-art EU-GMP certified facility is staffed by a team of 250 professionals and, as of 2023, is focused solely on providing CDMO services to its clients. Capacity is now available and our team is excited to engage in new projects.
More Case Studies: Managing Change In Vaccine Production

Jul 15, 2024 | advancingrna.com | Eric Doerr

Guest Column | July 15, 2024 By Eric Doerr, Manufacturing Sciences and Analytical Technology, Sanofi, Toronto Managing process and equipment changes for vaccine production processes requires, above all, transparent and meaningful communication between all stakeholders.
More Case Studies: Managing Change In Vaccine Production

Jul 15, 2024 | bioprocessonline.com | Eric Doerr

Guest Column | July 15, 2024 By Eric Doerr, Manufacturing Sciences and Analytical Technology, Sanofi, Toronto Managing process and equipment changes for vaccine production processes requires, above all, transparent and meaningful communication between all stakeholders.
06.25.24 -- Managing Change In Vaccine Production With All Stakeholders

Jun 25, 2024 | bioprocessonline.com | Eric Doerr |Samsung BioLogics

Tech Transfer strategies and best practices to optimize your clinical and commercial supplyTech Transfers for biological products are complex, challenging processes. Join us on July 11th for an insightful webinar on the critical aspects of technology transfer of either drug substance or drug product. This session will delve into the strategies and best practices for seamless tech transfer processes, ensuring regulatory compliance, and maintaining product quality and consistency.
Managing Change In Vaccine Production With All Stakeholders

Jun 12, 2024 | bioprocessonline.com | Eric Doerr

Guest Column | June 12, 2024 By Eric Doerr, Manufacturing Sciences and Analytical Technology, Sanofi, Toronto It is without question that the road toward full implementation, submission, and acceptance of a new product, technology, unit operation, and/or other significant process change within the scope of biopharmaceutical manufacturing is very rarely a straightforward one.
Managing Change In Vaccine Production With All Stakeholders

Jun 12, 2024 | advancingrna.com | Eric Doerr

Guest Column | June 12, 2024 By Eric Doerr, Manufacturing Sciences and Analytical Technology, Sanofi, Toronto It is without question that the road toward full implementation, submission, and acceptance of a new product, technology, unit operation, and/or other significant process change within the scope of biopharmaceutical manufacturing is very rarely a straightforward one.
Managing Change In Vaccine Production With All Stakeholders

Jun 12, 2024 | outsourcedpharma.com | Eric Doerr |Louis Garguilo

Guest Column | June 12, 2024 By Eric Doerr, Manufacturing Sciences and Analytical Technology, Sanofi, Toronto It is without question that the road toward full implementation, submission, and acceptance of a new product, technology, unit operation, and/or other significant process change within the scope of biopharmaceutical manufacturing is very rarely a straightforward one.